Consortium Tracking Tumor Mutations to Guide Lung Cancer Treatment, Clinical Trial Inclusion | GenomeWeb

By Andrea Anderson

CHICAGO (GenomeWeb News) – Members of the Lung Cancer Mutation Consortium are using genetic information to guide treatment and clinical trial participation for individuals with lung adenocarcinoma, Memorial Sloan-Kettering Cancer Center medical oncologist Mark Kris said at the American Society of Clinical Oncology annual meeting here yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.